oxaliplatin + topotecan

Oxaliplatin + topotecan is an investigational combination chemotherapy regimen consisting of two small molecule agents, oxaliplatin and topotecan. Oxaliplatin is a platinum-based antineoplastic that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. Topotecan is a topoisomerase I inhibitor that prevents DNA repair by stabilizing the cleavable complex between DNA and the enzyme, resulting in double-strand breaks during replication. The rationale for combining these drugs stems from evidence that platinum-induced DNA damage upregulates topoisomerase I activity, making tumor cells more susceptible to inhibition by agents like topotecan[1]. Preclinical studies have shown supra-additive (synergistic) effects on cancer cell death and tumor growth inhibition with this combination[1]. Clinical trials have primarily focused on advanced or recurrent ovarian cancer and other solid tumors; phase I/II studies established recommended dosing schedules and demonstrated manageable toxicity profiles along with preliminary evidence of clinical activity[1][3][4].

Other names

oxaliplatin + topotecan hydrochlorideoxaliplatin and topotecan